Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Ursula Creutzig, MD, PhD, Martin Zimmermann, PhD, Michael Dworzak, Jean-Pierre Bourquin, MD, PhD, Christine von Neuhoff, MD, Annette Sander, MD, Jan Stary, Dirk Reinhardt, MD

Blood (2012) 120 (21): 2621.

https://doi.org/10.1182/blood.V120.21.2621.2621

Published: 2012

Journal Articles

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

Alexandra Kolenova, MD, PhD, Katarina Reinhardt, PhD, Michaela Nathrath, MD, Claudia Rossig, MD, PhD, Arend von Stackelberg, MD, Christine von Neuhoff, MD, Annette Sander, MD, Peter Svec, MD, PhD, C. Michel Zwaan, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2011) 118 (21): 2539.

https://doi.org/10.1182/blood.V118.21.2539.2539

Published: 2011

Journal Articles

New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004

Christine von Neuhoff, MD, Annette Sander, MD, Jutta Bradtke, PhD, Silja Roettgers, PhD, Andrea Teigler-Schlegel, PhD, Martin Zimmermann, PhD, Johanna Ohlendorf, Nils von Neuhoff, PhD, Ursula Creutzig, MD, Dirk Reinhardt, MD, PhD

Blood (2010) 116 (21): 2741.

https://doi.org/10.1182/blood.V116.21.2741.2741

Published: 2010

Journal Articles

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

Annette Sander, MD, Martin Zimmermann, PhD, Dirk Reinhardt, MD, PhD, Michael Dworzak, MD, PhD, Gertjan Kaspers, MD, PhD, Ursula Creutzig, MD, PhD

Blood (2008) 112 (11): 963.

https://doi.org/10.1182/blood.V112.11.963.963

Published: 2008

Journal Articles

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

Katarina Reinhardt, PhD, Katarina Boehmer, Jan-Henning Klusmann, MD, Manuela Germeshausen, PhD, Annette Sander, MD, Christine von Neuhoff, MD, Jan Stary, MD, PhD, Heribert Jürgens, MD, PhD, Arnulf Pekrun, MD, PhD, Axel Sauerbrey, MD, PhD, Charlotte M Niemeyer, MD, PhD, Gudrun Fleischhack, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2008) 112 (11): 923.

https://doi.org/10.1182/blood.V112.11.923.923

Published: 2008

NARROW

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only